CombiGene AB (COMBI) AI Stock Analysis

• Market Cap: $49.11M
• Dividend Yield: 77.82%
• Average Volume (3M): 12.86K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.44
• Revenue Growth: -94.12%
• EPS Growth: -25.83%
• Country: SE
• Employees: 9
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 19,801,197
• 10 Day Avg. Volume: 17,097
• 30 Day Avg. Volume: 12,855
• PEG Ratio: 0.28
• Price to Book (P/B): 1.19
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -10.85
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: ―

CombiGene AB's overall stock score reflects substantial financial challenges, with declining revenues and negative cash flows being key risks. The technical analysis indicates a neutral trend, but the valuation remains unattractive due to ongoing losses. The lack of earnings call data and corporate events does not provide additional clarity or optimism for the stock's immediate outlook.

CombiGene AB Business Overview & Revenue Model

Company Description

CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.

How the Company Makes Money

CombiGene makes money primarily through the development and commercialization of its gene therapy products. The company generates revenue by partnering with larger pharmaceutical companies for the co-development, licensing, and distribution of its therapies. These partnerships often include upfront payments, milestone payments, and royalties on sales. Additionally, CombiGene may secure funding from grants and research collaborations with academic institutions and research organizations, which support the advancement of its therapeutic programs.

CombiGene AB Financial Statement Overview

Summary

CombiGene AB is facing substantial financial difficulties. Revenue has significantly declined, and the company is experiencing persistent losses with negative cash flows. Despite a strong equity base and no debt, the ongoing cash outflows present a risk to the company's financial health.

Income Statement

CombiGene AB's income statement reveals a challenging financial position with a significant decline in total revenue from 2021 to 2024. The company reported a negative net profit margin, indicating consistent losses. Additionally, the EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Despite previous revenue growth, recent figures show a sharp decline, negatively impacting the overall score.

Balance Sheet

The balance sheet analysis shows a strong equity position with no debt, leading to a favorable debt-to-equity ratio. The equity ratio remains high, which is a positive indicator of financial stability. However, the continuous depletion of cash reserves due to operational losses creates a potential risk if the trend continues.

Cash Flow

The cash flow statement highlights significant challenges, with negative free cash flow and operating cash flow, indicating cash outflows exceeding inflows. The free cash flow growth rate is concerning, with no positive growth trajectory. The operational cash flow to net income ratio is unfavorable, suggesting inefficiency in converting earnings to cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	326.00K	5.54M	26.70M	84.04M	10.83M
Gross Profit	-46.78M	-21.29M	-19.20M	15.16M	8.33M
EBITDA	-34.22M	-35.98M	-5.86M	23.56M	-25.66M
Net Income	-44.88M	-35.66M	-6.16M	20.96M	-30.77M
Balance Sheet
Total Assets	75.88M	120.61M	158.22M	166.22M	79.41M
Cash, Cash Equivalents and Short-Term Investments	73.75M	101.44M	131.78M	136.74M	48.90M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	4.30M	4.16M	6.10M	7.94M	7.98M
Stockholders Equity	71.58M	116.46M	152.12M	158.28M	71.43M
Cash Flow
Free Cash Flow	-29.95M	-30.67M	-16.67M	21.97M	-38.45M
Operating Cash Flow	-29.95M	-30.56M	-16.67M	22.11M	-38.35M
Investing Cash Flow	-81.00K	-988.90K	0.00	-147.73K	-3.21M
Financing Cash Flow	0.00	0.00	0.00	65.88M	75.29M

CombiGene AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.47
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:COMBI, the sentiment is Negative. The current price of 2.47 is above the 20-day moving average (MA) of 2.40, above the 50-day MA of 2.33, and above the 200-day MA of 2.27, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 45.19 is Neutral, neither overbought nor oversold. The STOCH value of 43.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:COMBI.

CombiGene AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$15.58B	5.65	-7.43%	4.32%	11.60%	-21.06%
COMBI	52 Neutral	$49.11M	―	-47.01%	77.82%	-94.12%	-25.83%
EXPRS2	49 Neutral	€68.05M	―	-66.45%	―	-36.71%	72.81%
MODTX	42 Neutral	kr44.56M	―	-222.24%	―	―	58.36%
ONCOZ	41 Neutral	kr81.99M	―	-46.84%	―	―	45.38%
SPRINT	39 Underperform	kr53.18M	―	-147.64%	―	30.02%	-3985.71%
SPAGO	38 Underperform	kr107.59M	―	-105.78%	―	58.72%	70.69%